Sanofi (NASDAQ:SNY) Receives $57.50 Average Target Price from Brokerages

Shares of Sanofi (NASDAQ:SNY) have earned an average recommendation of “Moderate Buy” from the five ratings firms that are covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $57.50.

SNY has been the topic of a number of research reports. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a report on Friday. Argus boosted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday.

Sanofi Price Performance

Shares of SNY opened at $57.63 on Friday. The firm has a market cap of $145.96 billion, a PE ratio of 28.96, a P/E/G ratio of 1.62 and a beta of 0.60. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a fifty day simple moving average of $54.34 and a two-hundred day simple moving average of $50.48.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. Sanofi’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.95 earnings per share. On average, equities analysts anticipate that Sanofi will post 4.25 EPS for the current year.

Institutional Trading of Sanofi

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Barrow Hanley Mewhinney & Strauss LLC grew its position in shares of Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after purchasing an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC raised its position in shares of Sanofi by 1,153.1% during the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after buying an additional 2,306,286 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after buying an additional 1,370,232 shares in the last quarter. Mondrian Investment Partners LTD lifted its holdings in shares of Sanofi by 43.1% in the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after buying an additional 1,190,141 shares in the last quarter. Finally, Armistice Capital LLC purchased a new position in Sanofi during the fourth quarter valued at $51,520,000. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.